United States Filgrastim Market Insight
Published: 16 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The United States Filgrastim Market is projected to grow at a CAGR of around 6.9% over the forecast period, driven by the increasing prevalence of cancer and expanding use of granulocyte colony-stimulating factor (G-CSF) therapies.
United States Filgrastim Market Forecasts to 2035
- The United States Filgrastim Market size was estimated at approximately USD 1.48 Billion in 2025.
- The market is expected to grow at a CAGR of around 6.9% from 2025 to 2035.
- The United States Filgrastim Market is projected to reach approximately USD 2.88 Billion by 2035.
Notable Insights for the United States Filgrastim Market
- Segmentation based on product type indicates that biosimilar filgrastim products account for nearly 54% of market revenue in 2025, supported by increasing physician confidence, cost-effectiveness, and broader reimbursement coverage.
- Segmentation based on application shows that chemotherapy-induced neutropenia (CIN) holds nearly 68% market share in 2025, driven by the high number of oncology patients receiving myelosuppressive chemotherapy.
- Growing adoption of biosimilars, self-administered injectable therapies, and hospital outpatient treatment programs contributes to more than 45% of new treatment utilization in 2025.
- Rising cancer incidence, increasing healthcare expenditure, improved access to biologics, and supportive reimbursement policies account for nearly 60% of the key market growth drivers.
Download the eBook (ToC)
Research Methodologies Used to Analyze United States Filgrastim Market
The United States Filgrastim Market is analyzed using primary and secondary research methodologies to ensure accurate market estimates and forecasts. Primary research includes interviews with oncologists, hematologists, hospital pharmacists, specialty pharmacy providers, biologics manufacturers, biosimilar developers, distributors, healthcare administrators, and industry experts. Secondary research covers company annual reports, FDA publications, healthcare databases, oncology journals, government healthcare statistics, reimbursement guidelines, and market intelligence databases. Data triangulation, competitive benchmarking, pricing analysis, regulatory assessment, market share evaluation, and statistical forecasting models are applied to validate findings and provide reliable market forecasts through 2035.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States Filgrastim Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Filgrastim Market
- Amgen Inc.
- Pfizer Inc.
- Sandoz Inc.
- Teva Pharmaceuticals USA, Inc.
- Viatris Inc.
- Fresenius Kabi USA
- Coherus BioSciences, Inc.
- Biocon Biologics Ltd.
- Accord BioPharma
- Dr. Reddy's Laboratories Inc.
Recent Developments:
- In May 2025, Biocon Biologics expanded the commercial availability of its biosimilar filgrastim products across the United States to strengthen oncology supportive care offerings.
- In February 2025, Amgen announced continued investments in biologics manufacturing and supply chain capabilities to support the growing demand for supportive oncology therapies in the U.S. market.
Market Segmentation:
United States Filgrastim Market, By Product Type
- Reference Filgrastim
- Biosimilar Filgrastim
United States Filgrastim Market, By Application
- Chemotherapy-Induced Neutropenia
- Bone Marrow Transplantation
- Chronic Neutropenia
- Peripheral Blood Progenitor Cell Mobilization
- Others
United States Filgrastim Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Online Pharmacies
Expert Views:
The United States Filgrastim Market is expected to witness steady growth through 2035, supported by increasing cancer prevalence, expanding use of biosimilar biologics, rising demand for supportive oncology care, and favorable reimbursement policies. Continued innovation in biologic manufacturing, improved patient access, and broader adoption of cost-effective biosimilars are expected to strengthen market growth. Furthermore, increasing investments in oncology treatment infrastructure, personalized cancer care, and healthcare system modernization are anticipated to create long-term opportunities for pharmaceutical manufacturers, biosimilar developers, healthcare providers, and specialty pharmacy organizations across the United States.
Author: Govind and Krishna By Decisions Advisors and Consulting